Boston Scientific Names Joseph M. Fitzgerald as Executive Vice President and COO

MARLBOROUGH, Mass., Oct. 7, 2026 /CourierPR/ -- Boston Scientific Corporation has announced the appointment of Joseph M. Fitzgerald as Executive Vice President and Chief Operating Officer (COO), effective January 1, 2027. This move is part of a broader restructuring aimed at enhancing operational efficiency and supporting the company's continued growth.

Fitzgerald, currently serving as Executive Vice President and Group President of Cardiovascular at Boston Scientific, brings extensive experience and a deep understanding of the company’s business and markets to the new role. His leadership has been instrumental in strengthening the company’s portfolio through organic innovation, strategic investments, and robust commercial execution. Fitzgerald will oversee the company’s global operations, business units, and regions, ensuring that Boston Scientific remains at the forefront of medical technology innovation.

In connection with Fitzgerald’s appointment, Boston Scientific will establish three reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg. These segments will go into effect on January 1, 2027. The new operating structure is designed to enable faster decision-making and support strategic allocation of investments across the company’s portfolio. Specifically, Lance Bates will lead the global Interventional Therapies segment, Nick Spadea-Anello will lead the global Rhythm Solutions segment, and Stephen Morse will serve as Executive Vice President and President of MedSurg and Asia Pacific.

Boston Scientific, a global medical technology leader for over 45 years, has transformed lives through innovative medical technologies that improve patient health. The company’s mission is to advance science for life by providing a broad range of high-performance solutions for complex medical conditions. Under Fitzgerald’s leadership, the company aims to continue its growth trajectory and maintain its position as a leader in the medical technology industry.

The restructuring reflects the scale and breadth of Boston Scientific’s business today and the opportunities ahead. The new operating model will create greater capacity to focus on long-term growth priorities while enabling the businesses to move faster and remain close to their customers and patients. Boston Scientific’s commitment to innovation and excellence is evident in its strategic decisions and the appointment of Fitzgerald, who is well-suited for the role due to his strong track record of execution and leadership.

Boston Scientific’s forward-looking statements are subject to various risks and uncertainties, including economic conditions, foreign currency fluctuations, political and regulatory changes, and manufacturing disruptions. The company will continue to navigate these challenges while focusing on its core mission of improving patient outcomes through advanced medical technologies.